Loading...
•
Jun 30, 2020
Ultragenyx Q2 2020 Earnings Report
Ultragenyx reported Q2 2020 financial results with two U.S. FDA approvals.
Key Takeaways
Ultragenyx reported a total revenue of $61.7 million for the second quarter of 2020, including Crysvita revenue in Ultragenyx territories of $32.4 million. The company also had two FDA approvals in the second quarter and maintained its full-year 2020 guidance.
Total revenue for Q2 2020 was $61.7 million.
Crysvita revenue in Ultragenyx territories reached $32.4 million.
Two new FDA approvals were obtained for Dojolvi and Crysvita.
Full year 2020 guidance for Crysvita revenue in Ultragenyx territories is maintained between $125.0 million and $140.0 million.
Revenue by Segment
Forward Guidance
The company continues to maintain its guidance range for 2020 Crysvita revenue in the Ultragenyx territories between $125.0 million and $140.0 million, but will continue to monitor the COVID-19 pandemic situation.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...